Swiss National Bank Sells 18,800 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Swiss National Bank reduced its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 653,500 shares of the medical equipment provider’s stock after selling 18,800 shares during the quarter. Swiss National Bank’s holdings in Zimmer Biomet were worth $79,531,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZBH. American Century Companies Inc. increased its holdings in Zimmer Biomet by 21.2% in the 3rd quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after acquiring an additional 852,186 shares during the last quarter. Boston Partners grew its stake in shares of Zimmer Biomet by 29.2% in the 3rd quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock worth $302,366,000 after buying an additional 608,959 shares in the last quarter. Barclays PLC grew its stake in shares of Zimmer Biomet by 129.2% in the 3rd quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider’s stock worth $120,356,000 after buying an additional 604,652 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Zimmer Biomet by 23.7% in the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock worth $345,452,000 after buying an additional 543,344 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth $57,972,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of recent research reports. Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 23rd. Citigroup lifted their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 9th. StockNews.com cut shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 19th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $135.40.

Zimmer Biomet Trading Up 2.7 %

Shares of ZBH opened at $121.66 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $147.50. The company has a 50-day moving average of $125.30 and a 200 day moving average of $120.02. The firm has a market capitalization of $25.00 billion, a price-to-earnings ratio of 26.33, a PEG ratio of 2.23 and a beta of 1.03. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.78.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter last year, the business posted $1.89 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet’s payout ratio is 20.78%.

Insider Activity at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is currently owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.